One year later, Jasmine had achieved a 22% total weight reduction, A1C of 6.0%, preserved lean mass, and resolved cravings
In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said that they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity
The Restaurant Challenge on GLP-1s Here's what makes restaurants tricky: Portion sizes are 2-3x what you need (most entrees are 800-1,200 calories) Hidden fats everywhere (butter, oil, cream sauces increase nausea risk) Limited protein-forward options (many menus emphasize carbs and fats) Social pressure to "enjoy yourself" (well-meaning friends encouraging you to indulge) Fast pacing (meals arrive quickly, making it easy to eat too fast) Despite these challenges, restaurant eating is absolutely manageable with the right strategies
What matters far more than which medication you choose is how you use it
